Department of Human Biology, Faculty of Natural Sciences, University of Haifa, Haifa 3498838, Israel.
Department of Human Biology, Faculty of Natural Sciences, University of Haifa, Haifa 3498838, Israel; Migal-Galilee Research Institute, Kiryat Shmona 11016, Israel.
Drug Discov Today. 2019 Apr;24(4):1017-1022. doi: 10.1016/j.drudis.2019.01.017. Epub 2019 Jan 31.
Therapeutic recombinant glycoproteins are important for both the biotechnological industry and clinical purposes. Given the rapid clearance of these proteins from the circulation, they have to be injected frequently to obtain optimal therapy. Several strategies have been developed to overcome this limitation, aiming to increase the half-life of such proteins in the circulation. These strategies included chemical attachment of polyethylene glycol, nanocapsulation, fusion to immunoglobulins or to albumin as protein carriers, or enrichment of the carbohydrate content. Here, we describe a strategy for increasing the half-life of recombinant proteins using gene fusion to increase the carbohydrate content of the protein backbone.
治疗性重组糖蛋白对于生物技术产业和临床应用都非常重要。由于这些蛋白质在血液循环中迅速清除，因此必须经常注射以获得最佳治疗效果。已经开发了几种策略来克服这一限制，旨在增加这些蛋白质在血液循环中的半衰期。这些策略包括化学连接聚乙二醇、纳米胶囊化、与免疫球蛋白或白蛋白融合作为蛋白质载体，或增加碳水化合物含量。在这里，我们描述了一种使用基因融合来增加蛋白质骨架的碳水化合物含量以增加重组蛋白半衰期的策略。
